Abstract:Rapid progress in molecular cancer biology coupled with the discovery of novel oncology drugs has opened new horizons for cancer target discovery. As one of the crucial signaling pathways related to tumorigenesis, hypoxia-inducible factor-1 (HIF-1) coordinates the activity of many transcription factors and their downstream molecules that impact tumor growth and metastasis. Accumulating evidence suggests that the transcriptional responses to acute hypoxia are mainly attributable to HIF-1α. Moreover, the overexpression of HIF-1α in several solid cancers has been found to be strongly associated with poor prognosis. Thus, pharmacological targeting of the HIF-1 signaling pathways has been considered as a new strategy for cancer therapy in the recent years. Although over the past decade, tremendous efforts have been made in preclinical studies to develop new HIF-1 inhibitors from natural products (reservoirs of novel therapeutic agents), to date, these efforts have not been successfully translated into clinically available treatments. In this review, we provide new insights into the bio-pharmacological considerations for selecting natural compounds as potential HIF-1 inhibitors to accelerate anti-cancer drug development. In addition, we highlighted the importance of assessing the dependency of cancer on HIF1A to shortlist cancer types as suitable disease models. This may subsequently lead to new paradigms for discovering more HIF-1 inhibitors derived from natural products and facilitate the development of potent therapeutic agents targeting specific cancer types.

Hypoxia inducible factor-1α and oral tumor therapy

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

[Hypoxia-Inducible Factor-1Alpha: a Promising Target for Tumor Therapy].

Hypoxia-mediated Activation of Hypoxia-Inducible Factor-1Α in Head and Neck Squamous Cell Carcinoma: A Review

Small Molecules Targeting HIF-1α Pathway for Cancer Therapy in Recent Years

Cancer Therapy by Targeting Hypoxia-Inducible Factor-1.

The Reseach Development of Hypoxia-inducible Factor-1 and Tumor Cell Apoptosis

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

Advances in the research and development of HIF-1 inhibitors

Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation

Recent Agents Targeting Hif-1 Alpha For Cancer Therapy

HIF-1α pathway: role, regulation and intervention for cancer therapy

Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?

Recent Progress in the Study on Antitumor Drugs Targeting Hypoxia-Inducible Factor-1

Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma.

The Role of HIF in Angiogenesis, Lymphangiogenesis, and Tumor Microenvironment in Urological Cancers

Effect of hypoxia-inducible factor -1(HIF-1) and target genes on malignant tumor progression

Progress of Hypoxia-inducing Factor 1

Hypoxia-inducible Factor-1 and Tumour Angiogenesis